Literature DB >> 17080240

Prognostic value of cytokeratin-positive bone marrow cells of gastric cancer patients.

Stephan Gretschel1, Christian Schick, Ulrike Schneider, Lope Estevez-Schwarz, Andreas Bembenek, Peter M Schlag.   

Abstract

BACKGROUND: Epithelial cells in the bone marrow of patients with gastric cancer suggest tumor dissemination; however, their prognostic implications are controversial. We prospectively evaluated the correlation of bone marrow findings, recurrence rate, and disease-free survival after long-term follow-up.
METHODS: Bone marrow were aspirated from both iliac crests and stained with monoclonal cytokeratin (CK)-18 antibody in 209 patients before their initial operation. Patients were followed up for a median of 56 months.
RESULTS: Overall, 39 (19%) of 209 patients and 15 (14%) of 109 R0-resected patients had CK-positive cells. CK-positive patients had more local, regional, and distant recurrence than CK-negative patients (P < .05). We found a significantly shorter disease-free survival (P < .05) in the patients with >2 CK-positive cells per 2 x 10(6) bone marrow cells (mean, 35 months) than in patients with <or=2 CK-positive cells per 2 x 10(6 )bone marrow cells (mean, 70 months) or in patients with no CK-positive cells (mean, 86 months). Multivariate analysis confirmed that >2 CK-positive cells per 2 x 10(6) bone marrow cells was an independent prognostic factor for tumor-related death (P < .05).
CONCLUSIONS: Not only the mere presence of CK-positive epithelial cells in bone marrow, but also the cell number, correlates with prognosis. Our findings suggest that classifying CK-positive bone marrow cells in these patients will facilitate future studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17080240     DOI: 10.1245/s10434-006-9039-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

Review 1.  [Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic surgical consequences].

Authors:  S Gretschel; A Bembenek; T Schulze; W Kemmner; P M Schlag
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

Review 2.  Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.

Authors:  Maurizio Romano; Francesco De Francesco; Giuseppe Pirozzi; Enrico Gringeri; Riccardo Boetto; Marina Di Domenico; Barbara Zavan; Giuseppe A Ferraro; Umberto Cillo
Journal:  Oncoscience       Date:  2015-05-15

3.  The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients.

Authors:  P Kolodziejczyk; A Pituch-Noworolska; G Drabik; J Kulig; A Szczepanik; M Sierzega; A Gurda; T Popiela; M Zembala
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

4.  Disseminated tumor cells in bone marrow of gastric cancer patients: correlation with tumor hypoxia and clinical relevance.

Authors:  Larissa Bubnovskaya; Antonina Kovelskaya; Lilya Gumenyuk; Irina Ganusevich; Lesya Mamontova; Victor Mikhailenko; Dmitry Osinsky; Sergej Merentsev; Sergej Osinsky
Journal:  J Oncol       Date:  2014-02-11       Impact factor: 4.375

Review 5.  The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma.

Authors:  Yan Xiang; Ting Yang; Bing-Yao Pang; Ying Zhu; Yong-Ning Liu
Journal:  Stem Cells Int       Date:  2016-08-17       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.